Grifols, ES0171996087

Grifols B triggers technical signal. Grifols stock sits 32.64 percent below EUR 15.01 target

Published on 10/21/2026 at 10:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half net profit rose 28.70 percent to EUR 227 million. Grifols stock costs EUR 10.11 on October 21, 2026, and revenue reached EUR 3.6 billion.

Technical signal and reporting date

Grifols B closed at EUR 6.57 above its EUR 6.56 25-day average on October 14, 2026.
First-half net profit rose 28.70 percent to EUR 227 million in the six months through June 2026.
Grifols stock was trading at EUR 10.11 at Lang & Schwarz on October 21, 2026 at 10:35 a.m. CEST.
Third-quarter results are scheduled for November 10, 2026.

Fotorealistische Plasma-Fraktionierungsanlage, Biotech-Produktion, unbeschriftete Industriehalle — Fotorealistische Ansicht einer Plasma-Fraktionierungsanlage zeigt Grifols S.A. ES0171996087 in moderner Biotech-Produktion mit Reinraumtechnik, Illustration mit AI erstellt.

Grifols B triggered a technical signal on October 15, 2026, while the consensus target for Grifols stock stood at EUR 15.01, according to Benzinga España. Grifols stock was trading at EUR 10.11 at Lang & Schwarz on October 21, 2026 at 10:35 a.m. CEST.

Grifols combines signal and risk

The technical signal came from Grifols B, which closed at EUR 6.57 on October 14, 2026, above its EUR 6.56 25-day average. The same Benzinga España report said 13 analysts placed the average target for Class A shares at EUR 15.01.

That target is 32.64 percent above the Lang & Schwarz price of EUR 10.11. The comparison is constructive, but the report also cited the open Gotham-related legal dispute in the United States as a risk for sentiment.

Three dates show the changing picture

On July 28, 2026, Grifols reported first-half revenue of EUR 3.6 billion and net profit of EUR 227 million, up 28.70 percent, on its Grifols investor relations page. On October 10, 2026, Wall Street Zen cut its rating from Buy to Hold, as reported by MarketBeat. On October 15, 2026, Benzinga España reported the EUR 6.57 technical close for Grifols B and the EUR 15.01 average target.

What date comes next?

Grifols is scheduled to present third-quarter results on November 10, 2026, according to Benzinga España. For investors, the next report will test whether the first-half profit improvement can support the valuation gap between the EUR 10.11 market price and the EUR 15.01 consensus target.

Price and upcoming results

Grifols develops plasma-derived therapies, diagnostics and other healthcare products. The company reported operating profit of EUR 326 million and operating cash flow of EUR 228 million in the second quarter of 2026.

The stock was trading at EUR 10.11 at Lang & Schwarz on October 21, 2026 at 10:35 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.